Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Govt to Discuss Platforms to Promote Expansion of Drug Makers into Emerging Markets
July 31, 2017
- MHLW Advisory Panel Backs Approval of Pfizer’s Palbociclib
July 28, 2017
- MHLW Council Recommends Switching of 4 APIs; Switching of Levonorgestrel for Emergency Contraception Disapproved
July 28, 2017
- Chuikyo Scrutiny Continues for Cost Calculation Pricing Formula
July 27, 2017
- Chuikyo Members at Odds over How to Proceed with “CEA” Debate
July 27, 2017
- Govt OKs Basic Policy for FY2018 Budget Requests
July 21, 2017
- Panel OKs 42.12 Million Yen Price Tag for Drug Makers’ MID-NET Use in PMS
July 20, 2017
- MHLW Panel to Discuss Zetia + Lipitor Combination Product on Aug. 1
July 20, 2017
- Shiozaki Says MHLW to Uphold 3-Year 1.5 Trillion Yen Cap in Social Security Cost Rise, CEFP Panelists Call for Further Curtailment
July 19, 2017
- Azithromycin under PMDA Risk Review for Acute Generalized Exanthematous Pustulosis
July 19, 2017
- MHLW to Take Strict Action on Bayer after Xarelto Survey Probe
July 19, 2017
- MHLW Panel Agrees to Compile Guidelines to Address Polypharmacy in the Elderly
July 18, 2017
- Gov’t Establishing System to Quickly Provide Unapproved Drugs to Developing Countries, Learning from Inadequate Response to Request for Avigan
July 18, 2017
- Pfizer’s Breast Cancer Med Palbociclib Up for MHLW Panel Review on July 27
July 14, 2017
- Drug Price Cut Only Way to Eke Out FY2018 Funding, though Pharmas Important: Top MD Bureaucrat
July 14, 2017
- MHLW Presents Draft Survey Sheet for “Willing-to-Pay” Costs in “CEA” Scheme: Chuikyo
July 13, 2017
- Chuikyo Starts Debate on Interim Report on CEA, Industry Hearings Slated for Next Meeting
July 13, 2017
- Alminoprofen Reclassified as Class 1 OTC Drug: MHLW
July 13, 2017
- Osaka Prefecture to Conduct Surprise Onsite Inspections of API Manufacturing Facilities in Wake of Acetaminophen Scandal
July 13, 2017
- Retired Vice Minister Happy to See Stage Set for Timely Price Revisions
July 12, 2017
ページ
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…